Contents

Why Now

A note on tone: The rest of this guide is clinical and data-driven. This section is intentionally different — it's the context for why this guide exists in February 2026 rather than February 2020.

For decades, longevity research was a quiet academic pursuit — or late-night supplement hype. That changed. As of early 2026, the first human trials of cellular reprogramming are active, the capital flowing in exceeds $4 billion, and for the first time, we have tools to measure whether interventions are actually working. This is the inflection point where the biology of aging becomes the medicine of rejuvenation.

The scale of investment tells the story. Altos Labs: $3 billion, a dream team of Nobel laureates. Retro Biosciences: $180 million seed from Sam Altman, now navigating a $1 billion round, targeting ten added healthy years. NewLimit (Brian Armstrong): $130 million raised, $45 million Series B led by Eli Lilly, valued at $1.62 billion. The pharmaceutical establishment now views aging as a targetable indication, not a destiny.

This capital is funding human data. In late 2025, the first participant was dosed with Retro's RTR242 in Adelaide — a small-molecule autophagy restorer targeting neurodegenerative decline. Simultaneously, Life Biosciences' ER-100 became the first-in-human trial of partial epigenetic reprogramming, targeting age-related vision loss as a beachhead for whole-body application. Meanwhile, GLP-1 agonists — originally diabetes drugs — proved their cardiovascular case in the SELECT trial (20% reduction in major events) and are becoming a foundational layer of longevity medicine for the general population.

The PEARL trial confirmed rapamycin's safety in healthy adults, with sex-specific benefits for women. Epigenetic clocks (GrimAge, DunedinPACE) now let us verify if interventions work without waiting twenty years. The TRIIM trial demonstrated a 2.5-year biological age reversal. For the first time, multiple independent approaches — senolytics, reprogramming, NAD+ restoration, autophagy boosters — are being tested in humans simultaneously. These aren't competing theories. They're different fronts in the same war.

The era of "hope and pray" is over. We've entered the era of "measure and modify." The technology is real, the trials are active, and the clock is being reset.

How to Read This Guide

Every intervention in this guide follows the same format. No spin, no marketing language — just what it does, what the evidence says, and what it costs:

Section 1 — Available Now

These exist. You can get them. Some require a prescription, some require a clinic, one requires just a credit card and a mailbox. Here's what the evidence actually says about each.

★

Exercise (VO2 Max, Strength Training, Zone 2)

5/5

Mechanism

We need to say this clearly: exercise is the single most powerful longevity intervention in existence. Nothing in this guide — no drug, no supplement, no clinic — comes close. Low VO2 max is associated with a 5x increase in all-cause mortality, worse than smoking. Strength training preserves muscle mass (sarcopenia prevention), bone density, and metabolic health. Zone 2 cardio (the pace where you can still hold a conversation) builds mitochondrial density and cardiovascular resilience. These aren't subtle effects — they are the largest mortality risk reductions in the entire epidemiological literature.

Refresh Metaphor: An engine displacement upgrade (V6 to V8) allowing higher performance with less strain.

Evidence

Mandsager et al. (2018, JAMA Network Open): 122,007 patients, highest fitness quintile had 80% lower mortality than lowest. Ruiz et al. (2008, BMJ): muscular strength independently associated with lower cancer mortality. Multiple RCTs confirm exercise reduces cardiovascular events, improves insulin sensitivity, enhances cognitive function, and slows biological aging (measured by epigenetic clocks).

Protocol

Zone 2 cardio: 150–180 min/week (cycling, walking, jogging — heart rate 60–70% of max). Strength training: 3x/week, compound movements, progressive overload. VO2 max work: 1–2x/week high-intensity intervals (4×4 min at 85–95% max HR). This combination targets cardiovascular, metabolic, and musculoskeletal aging simultaneously.

$0 (self-directed) – $3,000/yr (trainer + gym)

Mandsager et al. (2018, JAMA Network Open) — 122,007 patients: cardiorespiratory fitness was inversely associated with all-cause mortality with no upper limit of benefit.

Risks

Injury risk with improper form (especially lifting). Overtraining syndrome with excessive volume. Cardiac screening recommended before starting high-intensity protocols over age 40. Start gradually.

★

Sleep Optimization

5/5

Mechanism

Sleep is when your body runs its maintenance cycle. Glymphatic clearance removes amyloid-beta and tau proteins (the Alzheimer's hallmarks) from your brain — but only during deep sleep. Growth hormone secretion peaks during slow-wave sleep. Immune function, DNA repair, and memory consolidation all depend on consistent 7–9 hour sleep. Sleeping 5 hours a night increases all-cause mortality by 12%. Sleeping less than 6 hours doubles your risk of cardiovascular events. This isn't a lifestyle suggestion — it's a biological requirement that most adults are failing.

Refresh Metaphor: A nightly high-pressure power wash for a city street.

Evidence

Cappuccio et al. (2010, Sleep) — meta-analysis of 1.3 million people: short sleep (<6h) increased all-cause mortality 12%. Li et al. (2023, JAMA Internal Medicine): 5 sleep habits combined reduced all-cause mortality by 30% in men, 40% in women. Walker lab (UC Berkeley): chronic sleep deprivation reduces natural killer cell activity by 70% in a single night.

Protocol

Duration: 7–9 hours, non-negotiable. Consistency: Same bed/wake time ±30 minutes, including weekends. Environment: Cool (65–68°F/18–20°C), dark, quiet. Tracking: Oura Ring or WHOOP for sleep staging data. Interventions for poor sleepers: CBT-I (cognitive behavioral therapy for insomnia) before medication. Magnesium glycinate (200–400mg) and glycine (3g) before bed have modest evidence.

$0 (behavioral) – $500/yr (tracker + supplements)

Li et al. (2023, JAMA Internal Medicine) — 172,321 adults: adherence to 5 sleep factors associated with 4.7 years of added life expectancy in men, 2.4 years in women.

Risks

Sleep medication dependency (benzodiazepines, Z-drugs) is a real concern — avoid as first-line treatment. Undiagnosed sleep apnea affects ~30% of adults over 50; get tested if you snore or wake unrefreshed.

01

Rapamycin (Sirolimus)

3/5

The Origin — The Easter Island Freezer

In 1964, a Canadian medical expedition trekked across the Moai-strewn landscape of Easter Island, gathering soil samples that would ultimately reveal a chemical miracle. Among the dirt, a microbiologist discovered a bacterium secreting a potent antifungal compound they named Rapamycin, in honor of the island's native name, Rapa Nui. When the corporate research program was abruptly canceled years later, scientist Surendra Sehgal refused to let the discovery die, stashing the samples in his home freezer like a forbidden secret. Today, that rescued culture is the foundation of mTOR inhibition — a drug once destined for the trash that now represents our most robust pharmacological link to human life extension.

Mechanism

Your body has a master switch called mTOR that decides whether to grow or repair. After a certain age, it gets stuck on "grow" — which sounds good until you realize "grow" also means "age faster." Rapamycin flips it back to "repair," ramping up autophagy — your cells' built-in recycling system. It extends lifespan 15–30% in every animal model ever tested. No other drug comes close to this track record.

Refresh Metaphor: A factory manager stopping the assembly line to fix the machines.

Evidence

Strong animal evidence (replicated across species). PEARL trial (2025): 48-week RCT in 114 healthy adults showed safety and modest benefits. No human lifespan RCT yet.

Access

Prescription required (off-label). Available via longevity-focused telemedicine platforms. Typical protocol: 5-10 mg once weekly. Requires baseline bloodwork and periodic monitoring.

Providers

AgelessRx (agelessrx.com) — 100% online, patients 40+

Healthspan (gethealthspan.com) — Personalized dosing

Heally (getheally.com) — $149/mo subscription

Concierge longevity physicians — rapamycin.news

$77 – $290/month (drug + telehealth)

PEARL Trial (Mannick et al., 2025) — First safety RCT in healthy adults. Well tolerated. Women on 10mg showed improved lean mass and pain scores.

Risks

Mouth ulcers (most common), elevated lipids, impaired wound healing, possible immune effects at higher doses. Long-term safety in healthy adults unknown.

02

NAD+ Infusions & Precursors (NMN, NR)

2/5

The Origin — The Molecular Battery

The story began in 1906 with yeast bubbling in a London laboratory, where researchers first isolated a heat-stable "coferment" that supercharged the process of fermentation. For nearly a century, Nicotinamide Adenine Dinucleotide (NAD+) remained a quiet metabolic worker, until David Sinclair's lab at Harvard demonstrated that older mice could be "rejuvenated" to a youthful state simply by restoring this molecular fuel. This revelation ignited a billion-dollar industry, transforming a humble vitamin derivative into the high-stakes centerpiece of a global quest to recharge the human cellular battery.

Mechanism

NAD+ is the molecule your mitochondria need to produce energy and repair DNA. It's not optional — every cell in your body uses it. The problem: your levels drop roughly 50% by middle age. IV infusions deliver NAD+ directly into your bloodstream; oral precursors (NMN, NR) take the scenic route through your gut. The goal is simple — restore the cellular energy levels you had at 25. Whether that actually translates to living longer is the billion-dollar question.

Refresh Metaphor: Plugging a fading smartphone into a fast-charger.

Evidence

Animal studies show benefits. Human studies confirm NAD+ levels rise. No large RCT proves longevity benefit. NR-SAFE trial (2023): high-dose NR safe but mixed efficacy.

Providers

Restore Hyper Wellness (restore.com) — 200+ US locations

Next Health (next-health.com) — LA, NYC

AgelessRx — NAD+ patches, telehealth

Tru Niagen, ProHealth NMN — Oral supplements

IV: $250 – $1,500/session | Oral: $30 – $90/month

Brakedal et al. (2023, Nature Comms) — NR-SAFE trial. 3000mg/day NR safe in Parkinson's patients; modest brain NAD+ increase.

Risks

IV: nausea, flushing, headache. Oral: GI discomfort at high doses. Theoretical cancer concern (NAD+ fuels all cells) — no clinical evidence of this.

03

Therapeutic Plasma Exchange (TPE)

3/5

The Origin — The Dilution Insight

At Stanford in 2005, Michael and Irina Conboy performed a surgical feat of "vampiric" science, stitching together young and old mice to share a single circulatory system. While the world was mesmerized by the "young blood" narrative, the Conboys realized a deeper, darker truth: it wasn't just that young blood was magical, but that old blood was actively toxic. This pivotal insight shifted the focus from finding a fountain of youth to a process of "youthful recalibration" — removing the pro-aging inhibitors in old blood to let the body's resident stem cells wake up and heal again.

Mechanism

Here's the thing: your blood accumulates pro-aging garbage over time — inflammatory proteins, senescent cell signals, metabolic debris. TPE removes your plasma and replaces it with clean albumin. The breakthrough came from Irina Conboy's lab in 2020: it's not that young blood is magic — it's that old blood is toxic. Dilute the bad stuff and your body starts functioning younger. Dramatic concept. Early data.

Refresh Metaphor: An oil change for a high-performance engine (draining sludge, adding fresh oil).

Evidence

Strong mouse evidence. Buck Institute 2025 trial: TPE + IVIG reduced biological age by 2.61 years on multi-omic clocks. Small sample, short follow-up.

Providers

Circulate Health (circulate.health) — Seattle; 28 partners

Next Health (next-health.com) — LA, NYC

Kaplan Center (kaplanclinic.com) — McLean, VA

Neuroveda Health — Seattle, ~$5K/session

$5,000 – $10,000/session | Initial course: $15,000 – $60,000

Buck Institute/Circulate Health (2025, Aging Cell) — TPE + IVIG reduced biological age by 2.61 years using multi-omic biomarkers.

Risks

Hypotension, electrolyte imbalances, allergic reactions, fatigue. Diminishing returns noted after first 3 sessions. Very high cost relative to evidence.

04

Metformin

3/5

The Origin — The Medieval Lilac

Centuries before the first clinical trial, medieval healers brewed tea from the French lilac to soothe the insatiable thirst of the "sweet urine" disease. It took until 1957 for the French physician Jean Sterne to synthesize the plant's active essence into Metformin, a drug he aptly dubbed "Glucophage" or the "glucose eater." Now the most prescribed diabetes medication on Earth, this ancient herbal lineage has been repurposed by modern geroscience as a leading candidate to slow the biological clock itself.

Mechanism

Metformin costs less than your morning coffee and has more safety data behind it than almost any drug in existence. Originally a diabetes medication, it flips on AMPK — your body's caloric restriction switch — without requiring you to actually starve. It promotes autophagy, reduces inflammation, and may slow epigenetic aging. There's a genuine argument this should be in the water supply.

Refresh Metaphor: A "Low Fuel" warning light that tricks the car into driving more efficiently.

Evidence

Large observational studies suggest 15-30% mortality reduction in diabetic users vs. non-diabetics. TAME trial (3,000-person longevity RCT) planned since 2016, now finally enrolling after a decade of funding delays — a timeline that itself underscores how hard it is to fund aging research. MET-PREVENT: no improvement in physical function.

Providers

AgelessRx — $5-15/mo promotional pricing

Any primary care physician or endocrinologist

Fountain Life, Forward, Atria — Longevity protocols

SteadyMD, Lifeforce — Telehealth prescribing

$4 – $20/month (generic) — Cheapest longevity intervention

Bannister et al. (2014) — 78,000+ patients: diabetics on metformin had 15% lower all-cause mortality than non-diabetic controls.

Risks

GI side effects (diarrhea, nausea — common), B12 deficiency with long-term use, may blunt exercise adaptations. Generally well tolerated.

05

Senolytics (Dasatinib + Quercetin)

3/5

The Origin — Pruning the Zombie Cells

In the halls of the Mayo Clinic, Dr. Jim Kirkland began hunting "zombie cells" — damaged survivors that refuse to die, instead lingering to poison their healthy neighbors with a toxic inflammatory cocktail. The breakthrough came with the discovery that these cells have an "Achilles' heel": specific pro-survival networks that can be transiently disabled by a "hit-and-run" drug combination. When the first human swallowed a dose of Dasatinib and Quercetin in a 2019 pilot trial, it marked the moment we moved from treating symptoms to surgically pruning the dead wood of human aging.

Mechanism

As you age, some of your cells stop dividing but refuse to die. These "zombie cells" sit there leaking inflammatory chemicals that poison everything around them. Senolytics kill them. Dasatinib (a leukemia drug) and quercetin (a plant flavonoid) are the most studied combo — together they target multiple zombie cell types. The best part: you take them for 2–3 days and the effects last weeks to months. Hit and run.

Refresh Metaphor: A gardener pruning dead, rotting branches to let the tree breathe.

Evidence

Strong animal data (lifespan extension in mice). First-in-human (Kirkland, 2019): D+Q reduced senescent cell markers in 9 patients within 11 days. 2025 Alzheimer's pilot: safe, reduced inflammation. All human studies small.

Providers

TransformYou (transformyou.com) — D+Q protocols

Mayo Clinic trials — Active enrollment

Longevity-focused MDs (search A4M directory)

Some concierge practices prescribe off-label

$65 – $240/course (drug) | Clinic-supervised: $500 – $2,000+

Hickson, Kirkland et al. (2019, eBioMedicine/Lancet) — First proof that D+Q reduces senescent cells in living humans.

Risks

Dasatinib side effects at oncology doses are significant. At senolytic doses (short course), risks appear lower but not fully characterized. GI disturbance, no standardized dosing protocol yet.

06

GLP-1 Agonists (Semaglutide / Tirzepatide)

5/5

The Origin — The Gila Monster's Secret

In a Bronx VA laboratory, Dr. John Eng was obsessing over the saliva of the Gila monster, an Arizona lizard that can go months without a single meal. He discovered that the lizard's venom contained a hormone, exendin-4, that was nearly identical to human GLP-1 but resisted the rapid breakdown that usually happens in our blood. What began as a curiosity about lizard spit evolved into a pharmaceutical revolution, creating a multi-billion dollar class of drugs that not only manages weight but may protect the aging heart and brain.

Mechanism

These started as diabetes drugs and turned out to be something much bigger. GLP-1 receptors exist everywhere — heart, brain, kidneys, vasculature — and activating them reduces systemic inflammation, protects cardiovascular function, and may slow multiple aging pathways simultaneously. The weight loss is almost a side effect. Nature Biotechnology asked in 2025: "Are GLP-1s the first longevity drugs?" The honest answer: maybe.

Refresh Metaphor: A master thermostat turning down the heat (inflammation) in an overheated house.

Evidence

SELECT trial (2023, NEJM): 17,604 patients, semaglutide cut cardiovascular events 20%. ESSENCE trial: 62.9% NASH resolution. 2025 Lancet: 16% kidney failure risk reduction. Strongest human evidence base of any intervention on this list.

Providers

Any endocrinologist or PCP (most widely prescribed)

Hims/Hers (hims.com) — Large telehealth platform

Found (joinfound.com) — Metabolic health telehealth

Fountain Life, Noom Med, Calibrate

$150 – $1,350/month (insurance, brand vs. compounded)

Lincoff et al. (2023, NEJM — SELECT Trial) — Semaglutide reduced major cardiovascular events by 20% in overweight adults without diabetes.

Risks

GI side effects (nausea, very common initially), pancreatitis (rare), gallstones, muscle mass loss, "Ozempic face" (facial volume loss from rapid weight reduction), thyroid concern (rodent signal, unknown human relevance). 16.6% discontinuation rate. Muscle loss mitigation: Resistance training 3x/week is critical during GLP-1 therapy. The GLP-1 + Exercise for Muscle Preservation trial (NCT07091500) is actively studying this. High protein intake (1.6g/kg/day) also recommended.

07

Peptide Therapies (Epitalon, Pinealon, BPC-157, TA-1)

2/5

Epitalon (Epithalon) — The Pineal Refresh

Mechanism

Epitalon is a synthetic tetrapeptide that mimics a natural substance from the pineal gland. Its primary "Michelin" feature is telomerase activation—physically lengthening the protective caps on your DNA. It also recalibrates the circadian rhythm by boosting natural melatonin production, essentially "refreshing" the brain's internal clock to a more youthful state.

Refresh Metaphor: Adding new, strong plastic tips (aglets) to fraying shoelaces.

Evidence

Extensive Russian clinical data (Khavinson et al.) showing improved survival and immune function in elderly patients. Limited independent Western RCTs. Preclinical data for telomere lengthening is robust.

Protocol

5–10mg daily via subcutaneous injection for 10–20 days. Repeated 1–2 times per year. Subcutaneous is the only effective route; oral bioavailability is negligible.

$60 – $150 per cycle (10-day course)

Pinealon — The Neural Refresh

Mechanism

Pinealon is a short tripeptide that directly penetrates the blood-brain barrier and cell nuclei to modulate gene expression in neurons. It acts as a neuro-optimizer, reducing oxidative stress in the brain and stabilizing mitochondrial energy production. Think of it as a "Cellular Refresh" for the brain's hardware, improving memory retention and processing speed by protecting DNA from metabolic damage.

Refresh Metaphor: Defragmenting a computer hard drive for faster processing.

Evidence

Clinical observations show up to 30% improvement in memory retention and 50% in cognitive flexibility in Russian elderly cohorts. No large-scale Western Phase 3 trials. High safety profile in existing literature.

Protocol

2–5mg daily for 10–20 days. Often cycled alongside Epitalon for a combined systemic and neural refresh.

$50 – $120 per cycle

BPC-157 — The Structural Refresh

Mechanism

Originally discovered in gastric juice, BPC-157 is a 15-amino acid peptide focused on tissue repair. It accelerates the healing of tendons, ligaments, and the gut lining by promoting angiogenesis (new blood vessel growth). For the fitness-focused, it acts as a "Structural Refresh," allowing for faster recovery from injuries and chronic inflammation in the joints.

Refresh Metaphor: Scaffolding and fresh supply lines arriving at a construction site.

Evidence

Compelling animal data for soft tissue repair. ZERO published human RCTs. The FDA banned its compounding in 2024–2025 due to a lack of safety data, though it remains a staple in the "vanguard" longevity community.

Protocol

250–500mcg daily, typically subcutaneous near the injury site or oral for gut health. Usually cycled for 4–6 weeks.

$80 – $200 per course

Thymosin Alpha-1 — The Immune Refresh

Mechanism

Unlike experimental peptides, TA-1 is a medical-grade immune modulator. It trains your T-cells to be more precise, essentially rebooting the immune system's ability to distinguish between "self" and "enemy." It's the most established peptide for longevity-focused immune maintenance.

Refresh Metaphor: A drill sergeant training raw recruits into elite special forces.

Evidence

Strongest human data in the peptide category. Approved in 35+ countries for varied immune indications. Confirmed to improve vaccine response in the elderly.

$150 – $400 per month

Risks

Epitalon/Pinealon: No long-term Western safety data. Theoretical risk of fueling existing tumors (via telomerase). BPC-157: Lack of human safety data; unregulated quality. TA-1: High safety, but requires physician oversight. Unregulated "research chemical" sources carry high contamination risk.

08

Hormone Optimization (TRT, HGH, Bioidentical HRT)

4/5

Mechanism

Here's the deal: your hormones drop as you age. That's not opinion, it's lab work. The question is whether replacing them is medicine or vanity — and the answer depends entirely on which hormone. TRT for men (and women) with genuinely low testosterone? Well-supported. BHRT for menopausal women? Strong data when started within 10 years of menopause. HGH for "anti-aging"? The Endocrine Society says don't. Every anti-aging clinic says do. This is the single biggest fault line between mainstream medicine and the longevity world.

Refresh Metaphor: Tuning a radio from static back to a crystal-clear frequency.

Evidence

The big one: TRAVERSE trial (2023, NEJM, 5,246 men) finally proved TRT doesn't cause heart attacks — ending a decade of fear. Strong RCT data for hypogonadal men. BHRT: the WHI reanalysis flipped the script — benefits when started early. HGH: expert consensus remains firmly against anti-aging use. The clinics offering it aren't citing evidence. They're citing demand.

Providers

Ehormones MD (ehormones.com) — 30+ states, TRT/BHRT

ThriveLab (thrivelab.com) — Telehealth-based BHRT

HormoneSynergy — Portland, 25+ years BHRT

Virtually every anti-aging clinic offers this

TRT: $30 – $500/mo | BHRT: $30 – $500/mo | HGH: $500 – $4,700+/mo

TRAVERSE Trial (Lincoff et al., 2023, NEJM) — 5,246 hypogonadal men: TRT did NOT increase cardiovascular events (HR 0.99). Resolved a major safety debate.

Risks

TRT: erythrocytosis, acne, testicular atrophy, fertility suppression. BHRT: breast cancer risk (lower with bioidentical), blood clots. HGH: joint pain, insulin resistance, potential cancer promotion.

A Note for Women

Hormone optimization has fundamentally different considerations for women. The PEARL trial found sex-specific rapamycin benefits (lean tissue, pain) in women. BHRT timing relative to menopause onset is critical — the WHI reanalysis showed benefits when started within 10 years of menopause, but risks when started later. Perimenopause can begin in the early 40s, and estrogen decline accelerates bone loss, cardiovascular risk, and cognitive changes. Women should specifically seek physicians experienced in female hormone management, not just generalist "anti-aging" clinics. The protocol frameworks in this guide are gender-neutral composites — work with your physician to adjust for female-specific timing and dosing.

09

Hyperbaric Oxygen Therapy (HBOT)

2/5

The Origin — The Oxygen Paradox

Inside a high-pressure chamber in Tel Aviv, Dr. Shai Efrati began testing a theory that fluctuating oxygen levels could trick the body into a state of hyper-regeneration. The results of his 2020 study sent shockwaves through the community: participants who spent 90 days in the chamber saw their telomeres lengthen by up to 20%, a result far beyond any known lifestyle change. This "Holy Grail" moment proved that environmental signals alone could be used to physically elongate the protective caps on our chromosomes.

Mechanism

Sit in a pressurized chamber. Breathe pure oxygen. Do it 60 times. That's the protocol. The theory: repeated cycles of high oxygen trigger what's called the "hyperoxic-hypoxic paradox" — your body thinks it's suffocating and responds by mobilizing stem cells, growing new blood vessels, and in one Israeli study, lengthening telomeres by 20–38%. That single study is doing all the heavy lifting for HBOT's longevity reputation. It's genuinely impressive data — but it's one study, 35 people, no control group. That's not proof. That's a reason to watch closely.

Refresh Metaphor: A deep-sea diver returning to the surface (pressure change triggers reaction).

Evidence

Let's be honest about what we're working with: one trial. Efrati et al. (2020), 35 adults, 60 sessions. Telomeres lengthened 20–38%, senescent T cells dropped 10–37%. Dramatic numbers — from a small, single-arm study with no control group that hasn't been independently replicated. That's the entire evidence base for HBOT as a longevity intervention.

Providers

Aviv Clinics (aviv-clinics.com) — The Villages, FL; $45K

Bay Area Hyperbarics — San Jose; 26+ years

Hyperbaric Medical Solutions — Multiple locations

Restore Hyper Wellness — Select locations

$100 – $450/session | Aviv full program: ~$45,000 (60 sessions)

Hachmo, Efrati et al. (2020, Aging) — 60 HBOT sessions increased telomere length 20-38% and decreased senescent T cells 10-37% in adults 64+.

Risks

Barotrauma (ear/sinus), temporary myopia, seizures (rare, at high pressures), claustrophobia. Consumer soft-shell chambers do not replicate research protocols.

10

Exosome Therapy

1/5

Mechanism

Exosomes are the essential oils of longevity medicine. Lots of enthusiasm, almost no evidence. The concept is real — they're tiny vesicles that carry molecular cargo (proteins, RNA) between cells, and theoretically, exosomes from young cells could deliver "be young again" instructions to old ones. But the gap between concept and clinic is enormous. The FDA hasn't approved a single exosome product. People have been hospitalized from contaminated batches. Proceed with extreme skepticism.

Refresh Metaphor: A mail carrier delivering a specific instruction manual to a house.

Evidence

Preclinical ONLY. No FDA-approved exosome products. No published human longevity RCTs. FDA has issued multiple safety alerts. Patients in Nebraska were hospitalized from contaminated products. WEAKEST evidence of any intervention in this guide.

Providers

FDA has NOT approved any exosome products — extreme caution

Some clinics in FL, TX, CA offer under varying frameworks

Always verify GMP manufacturing, medical oversight

Consider waiting for clinical trial data

$2,000 – $18,000 (IV infusions, joint injections, packages)

Yin et al. (2024, Theranostics) — Comprehensive review documenting potential in preclinical models but critical gaps in clinical translation, dosing, and safety.

Risks

Contamination/infection (documented cases), unknown long-term effects, inconsistent product quality, potential tumor promotion, financial exploitation. No regulatory protections.

Section 3 — Diagnostics & Monitoring

You can't improve what you can't measure. These tools tell you how fast you're actually aging — and whether anything you're doing is working.

Section 5 — Where to Start

You don't need to do everything in this guide. You need to do the right things for your situation. Three inputs, one clear path.

Section 6 — Supplement Reference

Most supplements are money on fire. A few actually work. Here's which is which — rated by evidence, not by influencer sponsorship.

Section 7 — Interaction & Safety Reference

Before you stack five things from this guide, read this page. Some combinations are fine. Some will land you in the ER. This is the cheat sheet your doctor probably doesn't have.

Protocol Frameworks by Archetype

Four people, four budgets, four strategies. These aren't hypothetical — they're composites of real conversations. Not medical advice. Starting points for yours.

How to Spot a Bad Longevity Clinic

Read this before the Provider Directory. Before you book a flight or write a check.

The longevity medicine space is booming — and so are the clinics that will happily take your money for interventions backed by nothing more than a slick website and a confident physician. Before you write a check, run through these filters.

The most expensive clinic is not necessarily the best one. The best clinic is the one that shows you data, admits uncertainty, and changes your protocol based on your results.

Section 8 — Provider Directory

Where to actually go. US clinics and platforms, vetted and categorized.

Verified as of February 2026. Clinics change services, pricing, and availability. Check websites before booking.

INTERNATIONAL CLINICS

Curated clinics offering core longevity interventions outside the US. Medical facilities only — no spas, no aggregators.

Section 9 — What Comes Next

Three scenes from the near future of longevity medicine — where the science, the clinics, and the social consequences converge.

These scenarios are entirely fictional projections. All clinic names, physician names, and technologies are used speculatively to illustrate plausible futures — not to represent actual plans, endorsements, or predictions by any named individual or institution.

2028 — The First Results

The sun hasn't quite cleared the Minster in Basel, but the espresso machine at Origin Health has been hissed into submission since 4:00 AM. Dr. Manuel Puntschuh isn't looking at the Rhine; he is looking at a PDF of the Nature Aging paper that just broke the embargo.

The headlines call it "The Basel Protocol." For the first time, a trial using a localized epigenetic reprogramming transient has shown a statistically significant reversal in the DunedinPACE "speed of aging" clock. In the clinic's minimalist lounge, the air is thick with the scent of high-end clinical disinfectant and the quiet vibration of three simultaneous INUSpheresis machines. The "First Results" aren't just data points; they are the people in those chairs.

The shift is instantaneous. The previous era — the era of merely inhibiting mTOR with rapamycin — is suddenly "Longevity 1.0." By 10:00 AM, the waiting list for Puntschuh's "re-calibration" cycle has tripled. But the tension is palpable in the local pharmacy nearby. The "Reprogramming Gap" has officially opened. In the villas of Zurich, clients are prepaying $80,000 for a six-month cycle. On the streets below, the biological clock continues to tick at the standard, cruel rate. The first results have proven time is a variable, but only for those with the right Swiss bank account.

2032 — The Pill

The lobby of DNA Health & Wellness in Dubai feels less like a clinic and more like a private spaceport. Through the floor-to-ceiling glass, the Burj Khalifa pierces a heat haze that the world's elite now pay to ignore. On the low marble tables sit small, sapphire-blue canisters. Inside is the "Blue Alpha" — the first small-molecule reprogramming drug to enter Phase 3.

The "Pill" has replaced the complex IV cocktails of the late twenties. A visit to DNA Health is now a high-velocity data audit. A patient walks in, swipes a finger for a "Live-Clock" methylation check, and receives a month's supply of the Alpha molecule, precisely dosed to their current liver-aging markers. INUSpheresis is no longer the main event; it's merely the "biological prep" used to clear the systemic "noise" before the drug begins its work on the genome.

But the documentary lens pans out to the "Old Districts." The "Alpha" is $4,000 a month, and the patent is guarded more fiercely than oil reserves. In the AEON Clinic downstairs, the "Silver Tier" patients — those who can only afford the generic NAD+ and older stem cell protocols — look at the Blue Alpha users with a new kind of resentment. It isn't just a wealth gap anymore; it is a metabolic divergence. The "Alphas" move with a predatory, 25-year-old grace, even as their passports list them in their sixties.

2040 — The New Normal

Tuesday morning in Sydney. David, aged 72, is finishing a 5km sprint along Bondi Beach. His heart rate recovery is identical to that of his 28-year-old grandson, who is currently struggling to keep up. David's "Infinitum" dashboard, projected onto his bathroom mirror back at the Longevity Medicine Institute, shows his biological age holding steady at 34.2.

Longevity medicine is no longer "medicine"; it is a utility, like high-speed internet. Every three months, David visits LMI for a "Systemic Refresh." The visit is mundane. He sits in a 2.0 ATA hyperbaric pod, breathes a proprietary oxygen-xenon mix, and receives a subcutaneous patch that slowly releases the latest epigenetic "patches" over the next ninety days. The "New Normal" is a world where 70 is the peak of professional life, not the end of it.

But the "Michelin" edge has sharpened into a jagged social hierarchy. In the LMI lounge, the "Core" members — those who could only afford the basic cancer screenings — watch the "Infinitum" elite receive their neuro-regenerative exosomes. The documentary ends not on a hospital bed, but on a playground. David's grandson looks at him not with affection, but with the exhaustion of a generation that will never inherit, because the generation above them has simply refused to grow old.